



No. 07-030529- -00007-0000

Fecha: 2012-07-23 16:52:29 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 329 CTOINFORMACION Folios: 18

FORMULARIO UNICO DE CORRECCIONES Y MODIFICACIONES

1

SOLICITUD DE

☐

Corrección de Error Material

☒

Modificación de una solicitud

2

SOLICITANTE

Nombre: PFIZER IRELAND PHARMACEUTICALS

Dirección: Operations Support Group, Ringaskiddy, County
Cork, Irlanda

Nacionalidad o Domicilio: Irlanda

Lugar de Constitución: Irlanda

Teléfono:

Fax:

E-Mail

IDENTIFICACION

C.C. ☐

NIT ☐

C.E. ☐

Otro ☐

Cual

Número

3

REPRESENTANTE
O APODERADO

Nombre: ALVARO CORREA ORDOÑEZ

Dirección: Avenida 82 No.10-62 Piso 6o.

Teléfono: 634 1500

Fax: 376 2211

E-Mail: Alvaro.Correa@bakermckenzie.com

IDENTIFICACION

C.C. ☒

NIT ☐

C.E. ☐

Otro ☐

Cual

Número 79.143.366 TP 20.281

4

Numero de expediente

07.030.529

5

Descripción de la corrección o modificación solicitada

Traspaso de la solicitud, así:

DE: WYETH RESEARCH IRELAND LIMITED

A: PFIZER IRELAND PHARMACEUTICALS

6

Comprobante de Pago No.

12-0070163

Fecha 10-07-2012

7

Anexos

☒

Comprobante de pago de la tasa.

☒

Poderes, si fuere el caso.

☒

Documento que acredita la existencia y representación legal de las partes, cuando sean personas jurídicas.

8

NOMBRE ALVARO CORREA ORDOÑEZ

FIRMA

C.C. 79.143.366

T.P. 20.281

Instrucciones para el diligenciamiento del presente formulario, ver reverso de esta página.

2000-F03

87007/000034



Baker & McKenzie Colombia S.A.
NIT: 900.034.906-9

Av. 82 No. 10-62 6th Floor
Bogotá
Colombia

Tel: +57 1 634 1500
Fax: +57 1 376 2211
www.bakermckenzie.com

POWER OF ATTORNEY

The undersigned.

PFIZER IRELAND PHARMACEUTICALS

located at

**Operations Support Group, Ringaskiddy, County Cork,
Ireland.**

declares that it hereby grants to

**ÁLVARO CORREA-ORDÓÑEZ and/or
RICARDO METKE MENDEZ and/or JUAN PABLO
CONCHA-DELGADO and/or
OLGA GEORGETTE OTERO**

of the firm Baker & McKenzie Colombia S.A members of Baker & McKenzie, domiciled at Av. 82 No. 10-62, 6th floor, of Bogotá D.C., Colombia, full and sufficient power of attorney to pursue before the competent authorities the following matters:

Trademark registrations and renewals; deposit and registration of commercial names and commercial ensings; registration and renewal of domain names; Prosecution and obtainment of patents, utility models, industrial designs, integrated circuits layout-designs and vegetal varieties; recordals of mergers, changes of name, assignments, changes of domicile and address; security interests; liens and other acts that affect or limit the mentioned industrial property rights; filing and prosecution of oppositions; recordal of license of use agreements; filing and prosecution of cancellation actions, annulment actions, annulment and reinstatement of right action, and all judicial actions available for the prosecution of proceedings related to intellectual property matters, unfair competition, and protection of consumers.

to which end it empowers them to file requests, petitions and lawsuits, appeals and objections, pay taxes, receive, including faculties to enter into settlement agreements, conciliations and transactions, abandon applications and renounce rights and, in general, to take all the actions before the competent authorities in order to duly protect our intellectual property. To the said mandatories sufficient power is granted hereby to receive notifications for and on behalf of the Company, to confer powers on those who are to represent the Company judicially and extrajudicially, to answer in court in the matter of all claims and demands that may be presented in connection with the marks and other intellectual property rights, and to do everything that may be required before administrative or judicial officers of any class to comply this power, giving them likewise faculty to substitute these presents and revoke such substitutions if necessary.

PODER

La abajo firmada,

PFIZER IRELAND PHARMACEUTICALS

domiciliada en

declara por el presente que otorga a

**ÁLVARO CORREA-ORDÓÑEZ y/o RICARDO METKE
MÉNDEZ y/o JUAN PABLO CONCHA-DELGADO y/o OLGA
GEORGETTE OTERO**

de la firma Baker & McKenzie Colombia S.A., miembros de Baker & McKenzie, domiciliada en la Av. 82 No. 10-62 Piso 6 en Bogotá D.C., Colombia, poder especial amplio y suficiente, para adelantar ante las autoridades competentes los siguientes asuntos:

Registro y renovación de marcas; depósito y registro de nombres comerciales y enseññas comerciales; registro y renovación de nombres de dominio; trámite y obtención de solicitudes de patentes de invención, modelos de utilidad, diseños industriales, esquemas de trazado de circuitos integrados y variedades vegetales; inscripción de fusiones, cambios de nombre, traspasos, cambios de domicilio y de dirección; inscripción de contratos de prenda, embargos y otros actos que afecten o limiten los mencionados derechos de propiedad industrial; presentación y tramitación de oposiciones; inscripción de licencias de uso; presentación y tramitación de acciones de cancelación; acciones de nulidad, acciones de nulidad y restablecimiento del derecho y demás acciones judiciales, relacionadas con procesos de propiedad industrial, competencia desleal y protección al consumidor.

a cuyo efecto los faculta para presentar solicitudes, peticiones y demandas, interponer recursos, reclamos, pagar impuestos y tasas, recibir, transigir y desistir, incluyendo facultades para entrar en acuerdos amigables, conciliaciones y transacciones, abandonar solicitudes y renunciar a derechos, y en general, a dar ante las autoridades competentes todos los pasos necesarios para la debida protección de nuestra propiedad industrial. Asimismo se concede a los expresados mandatarios poder suficiente para recibir notificaciones a nombre de la compañía, otorgar poderes a quienes vayan a representar a la compañía judicial y extrajudicialmente, responder en juicio a todas las reclamaciones o demandas que por motivo de marcas y otros derechos de propiedad industrial se presentaren y hacer cuanto fuere necesario ante las autoridades administrativas o judiciales de cualquier orden para el cumplimiento de este mandato, dándoles igualmente facultad para sustituir el presente poder y en caso necesario, revocar dichas sustituciones.



Done and subscribed in Dublin, Ireland

Dado y firmado en Dublin, Irlanda

On the 19th day of June 2012

A los 19 días del mes de Junio de 20 12

Present when the common seal of PFIZER IRELAND PHARMACEUTICALS was affixed to this deed and this deed was delivered:

Diligenciado cuando el sello común de PFIZER IRELAND PHARMACEUTICALS se estampó a este documento.


Director PAUL DUFFY

PAUL DUFFY
Director


~~Director/Secretary~~
PETER DUFFY
Signature of the person Issuing the Power

PETER DUFFY
Director/

Firma de la persona que firma el Poder

This is a certified True copy of the

Original document



Dated the 18th day of April 2012

Patrick J.A. Kelly

Patrick J. A. Kelly
5 Harbourmaster Place
IFSC Dublin 1

Notary Public County & City of Dublin

ASSIGNMENT




For valuable consideration, the receipt and adequacy of which is hereby acknowledged, **Wyeth Research Ireland Limited**, a private limited company incorporated in Ireland (registered number 403603) whose registered office is at Little Connell, Newbridge, County Kildare, Ireland, hereby sells, assigns and transfers unto **Pfizer Ireland Pharmaceuticals**, a private unlimited company incorporated in Ireland (registered number 490938) having its registered office at Operations Support Group, Ringaskiddy, County Cork, Ireland, its entire right, title, and interest in and to any patent application or patent in which it has right, title, or interest, including its entire right, title and interest in and to the patent applications and patents listed in the Schedule attached hereto and expressly made a part hereof; its entire right, title and interest, in all countries of the world, in and to all inventions disclosed in said patent applications and patents; its entire right, title and interest in and to all continuations, divisions, continuations-in-part, reissues, reexaminations and extensions thereof; its entire right, title, and interest in and to all patent applications and patents in all countries of the world claiming priority from the patent applications and patents listed in the Schedule, its entire right, title, and interest, if any, in and to all patent applications and patents in all countries of the world from which the patent applications and patents listed in the Schedule claim priority, and the right to claim priority from any such patent application or patent under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America and/or Ireland is a party and which afford similar priority-claiming privileges, in all countries of the world; as well as the right to sue in the name of **Pfizer Ireland Pharmaceuticals** and recover damages for past infringement of any patent application or patent assigned hereby;

And **Wyeth Research Ireland Limited** hereby agrees, whenever requested, to communicate to said **Pfizer Ireland Pharmaceuticals** and its successors and assigns, any facts known to it respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world;


And **Wyeth Research Ireland Limited** authorizes **Pfizer Ireland Pharmaceuticals** or its designee to supply any missing patent application or patent identification information or correct any errors in the patent application or patent identification information provided herein whether discovered prior to or after recordation;

And Wyeth Research Ireland Limited hereby appoints Pfizer Ireland Pharmaceuticals, through its designee, its attorney-in-fact to execute, in its name and on its behalf, any and all documents required to effectuate this Assignment, including but not limited to further assignments, corrective assignments, powers of attorney and other papers.


PRESENT when the common seal of
Wyeth Research Ireland Limited
was affixed hereto and this deed was delivered:

By: 
Name: Peter Duffy
Title: Director
Nationality: Irish
Commercial Address:
LITTLE CONNELL
NEWBRIDGE
CO. KILDARE

Witnessed by:


By: 
Name: MUIREANN MANGAN
Title: LEGAL COUNSEL
Nationality: IRISH
Commercial address: RINGASKIDDY
CORK

Witnessed by:


By: 
Name: TONI COGGAN
Title: EXEC. ASSISTANT
Nationality: IRISH
Commercial address: RINGASKIDDY
CO. CORK

By: 
Name: Paul Duffy
Title: Director
Nationality: Irish
Commercial Address:
LITTLE CONNELL
NEWBRIDGE
CO. KILDARE


Witnessed by:


By: 
Name: MUIREANN MANGAN
Title: LEGAL COUNSEL
Nationality: IRISH
Commercial address: RINGASKIDDY,
CO. CORK

Witnessed by:

By: 
Name: TONI COGGAN
Title: EXEC. ASSISTANT
Nationality: IRISH
Commercial address: RINGASKIDDY
CO. CORK

The above signature(s) of Peter Duffy
and Paul Duffy
are hereby authenticated.

Dated this 5th day of April 2012




Patrick J. A. Kelly
5 Harbourmaster Place,
I.F.S.C
Dublin 1.
Notary Public for the County and City
Dublin Commissioned for Life.

PRESENT when the common seal of
Pfizer Ireland Pharmaceuticals
was affixed hereto and this deed was delivered:

By: *Peter Duffy*

Name: Peter Duffy

Title: Director

Nationality: Irish

Commercial Address:

*Pfizer Ireland Pharmaceuticals
Ringaskiddy
Co. Cork*

By: *Paul Duffy*

Name: Paul Duffy

Title: Director

Nationality: Irish

Commercial Address:

*Pfizer Ireland Pharmaceuticals
Ringaskiddy
Co. Cork*

Witnessed by:

By: *Muiréann Mangan*

Name: MUIREANN MANGAN

Title: LEGAL COUNSEL

Nationality: IRISH

Commercial address: RINGASKIDDY
CO. CORK

By: *Muiréann Mangan*

Name: MUIREANN MANGAN

Title: LEGAL COUNSEL

Nationality: IRISH

Commercial address: RINGASKIDDY
CO. CORK

Witnessed by:

By: *Toni Coggin*

Name: TONI COGGIN

Title: EXEC. ASSISTANT

Nationality: IRISH

Commercial address: RINGASKIDDY
CO. CORK

By: *Toni Coggin*

Name: TONI COGGIN

Title: EXEC. ASSISTANT


Nationality: IRISH

Commercial address: RINGASKIDDY
CO. CORK

The above signature(s) of *Peter Duffy*
and *Paul Duffy*
is/are hereby authenticated.

Dated this *5th* day of *April* 2012

Patrick J. A. Kelly



3 of 3

Patrick J. A. Kelly
5 Harbourmaster Place,
I.E.S.C
Dublin 1.

Notary Public for the County and City of
Dublin Commissioned for Life.

Docket Number	Country	Application Number	Application Date	Patent Number	Grant Date	Expiration Date	Title
35059	Albania	5791482.2	26-Aug-05	AL-P-2009-3226	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Albania	AL-P-2010-3382	28-Mar-08	3323	13-Oct-10	26-Aug-25	Production Of Etanercept
35059	Argentina	P050103596	26-Aug-05				Production Of Etanercept
35060	Argentina	P050103595	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Argentina	P050103594	26-Aug-05				Production Of Polypeptides
35059	Australia	2005280036	26-Aug-05	2005280036	16-Feb-12	26-Aug-25	Production Of Etanercept
35060	Australia	2005280090	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35060	Australia	2012200353	20-Jan-12				Production Of Anti-Amyloid Beta Antibodies
50640	Australia	2006215313	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	Australia	2005280034	26-Aug-05				Production Of Polypeptides
35059	Austria	5791482.2	26-Aug-05	E446376	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Austria	8005732.6	28-Mar-08	E461285	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Belgium	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Belgium	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Bosnia-Herzegovina	5791482.2	26-Aug-05	1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Bosnia-Herzegovina	8005732.6	28-Mar-08	1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Brazil	PI 0514694-1	26-Aug-05				Production Of Etanercept
35060	Brazil	PI0514680-1	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
50640	Brazil	PI0607269-0	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	Brazil	PI0514703-4	26-Aug-05				Production Of Polypeptides
35059	Bulgaria	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Bulgaria	8005732.6	28-Mar-08	BG/EP1992697T3	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Canada	2578136	26-Aug-05	2578138	05-Oct-10	26-Aug-25	Production Of Etanercept
35060	Canada	2578137	26-Aug-05	2578137	09-Nov-10	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
50640	Canada	2594580	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	Canada	2578141	26-Aug-05				Production Of Polypeptides
35059	Chile	2183/2005	26-Aug-05				Production Of Etanercept
35060	Chile	2185/2005	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Chile	2184/2005	26-Aug-05				Production Of Polypeptides
35059	China P.R.	200580036936.8	26-Aug-05				Production Of Etanercept
35060	China P.R.	200580036897.2	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
50640	China P.R.	200680003134.2	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	China P.R.	200580036899.1	26-Aug-05				Production Of Polypeptides
35059	Colombia	07 030 535	26-Aug-05				Production Of Etanercept
35060	Colombia	7030534	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Colombia	07 030 529	26-Aug-05				Production Of Polypeptides
35059	Costa Rica	8998	26-Aug-05				Production Of Etanercept
35060	Costa Rica	8996	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Costa Rica	8997	26-Aug-05				Production Of Polypeptides
35059	Croatia	5791482.2	26-Aug-05	P20100211	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Croatia	8005732.6	28-Mar-08	P20100271	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Cyprus	5791482.2	26-Aug-05	CY1109721	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Cyprus	8005732.6	28-Mar-08	CY1110092	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Czech Republic	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept

35059	Czech Republic	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Denmark	5791482.2	26-Aug-05	1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Denmark	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Ecuador	SP-07-7354	26-Aug-05				Production Of Etanercept
35060	Ecuador	SP-07-7351	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Ecuador	SP-07-7353	26-Aug-05				Production Of Polypeptides
35059	Egypt	222/2007	26-Aug-05				Production Of Etanercept
35060	Egypt	224/2007	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Egypt	223/2007	26-Aug-05				Production Of Polypeptides
35059	El Salvador	E-2211-2005	26-Aug-05				Production Of Etanercept
35060	El Salvador	E-2212-2005	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35059	Estonia	5791482.2	26-Aug-05	E004067	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Estonia	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	European Patent Convention	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	European Patent Convention	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35060	European Patent Convention	5791655.3	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35060	European Patent Convention	10184494.2	30-Sep-10				Production Of Anti-Amyloid Beta Antibodies
50640	European Patent Convention	6744688	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	European Patent Convention	5792494.6	26-Aug-05				Production Of Polypeptides
52009	European Patent Convention	11156236.9	28-Feb-11				Production Of Polypeptides
35059	Finland	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Finland	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	France	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	France	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Germany	5791482.2	26-Aug-05	6.02005E+11	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Germany	8005732.6	28-Mar-08	6.02005E+11	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Great Britain	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Great Britain	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Greece	5791482.2	26-Aug-05	3070847	21-Oct-09	27-Aug-25	Production Of Etanercept
35059	Greece	8005732.6	28-Mar-08	3071852	17-Mar-10	27-Aug-25	Production Of Etanercept
35059	Guatemala	PI-2005-0234	26-Aug-05	5479	05-May-10	26-Aug-25	Production Of Etanercept
35060	Guatemala	PI-2005-0233	26-Aug-05	5245	19-Feb-08	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
35059	Gulf Cooperation Council	GCC/PI/2005/5622	26-Dec-05				Production Of Etanercept
35060	Gulf Cooperation Council	GCC/PI/2005/5623	26-Dec-05				Production Of Anti-Amyloid Beta Antibodies
35059	Honduras	PI/2005/485	26-Aug-05	4821	22-Sep-09	26-Aug-25	Production Of Etanercept
35060	Honduras	PI/IE/2005/486	26-Aug-05	4906	02-Aug-10	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
35059	Hong Kong	9102050.2	18-Jul-07	1121497B	20-May-10	26-Aug-25	Production Of Etanercept
35059	Hong Kong	7107585.9	16-Jul-07	1099941B	08-Jan-10	26-Aug-25	Production Of Etanercept
35060	Hong Kong	7107713.4	18-Jul-07				Production Of Anti-Amyloid Beta Antibodies
52009	Hong Kong	7107390.4	10-Jul-07				Production Of Polypeptides
35059	Hungary	5791482.2	26-Aug-05	E007218	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Hungary	8005732.6	28-Mar-08	E008223	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Iceland	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Iceland	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	India	2317/DELNP/2007	26-Aug-05				Production Of Etanercept

35059	India	5860/DELNP/2011	01-Aug-11				Production Of Etanercept
35060	India	2314/DELNP/2007	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
50640	India	5543/DELNP/2007	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	India	2315/DELNP/2007	26-Aug-05				Production Of Polypeptides
35059	Indonesia	W00200700657	26-Aug-05				Production Of Etanercept
35060	Indonesia	W00200700659	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Indonesia	W00200700658	26-Aug-05				Production Of Polypeptides
35059	Ireland	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Ireland	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Israel	181588	26-Aug-05	181588	31-Mar-11	26-Aug-25	Production Of Etanercept
35060	Israel	181587	26-Aug-05	181587	01-Jul-11	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
50640	Israel	184247	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	Israel	181589	26-Aug-05				Production Of Polypeptides
35059	Italy	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Italy	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Japan	2007-530167	26-Aug-05				Production Of Etanercept
35059	Japan	2012-033112	17-Feb-12				Production Of Etanercept
35060	Japan	2007-530148	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35060	Japan	2012-033105	17-Feb-12				Production Of Anti-Amyloid Beta Antibodies
50640	Japan	2007-552756	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	Japan	2007-530166	26-Aug-05	4864892	18-Nov-11	26-Aug-25	Production Of Polypeptides
35059	Korea South	10-2007-7004810	26-Aug-05	10-9988451	12-Oct-10	26-Aug-25	Production Of Etanercept
35060	Korea South	10-2007-7004809	26-Aug-05	10-998857	01-Dec-10	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
50640	Korea South	10-2007-7017130	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	Korea South	10-2007-7004807	26-Aug-05				Production Of Polypeptides
35059	Latvia	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Latvia	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Lithuania	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Lithuania	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Luxembourg	5791482.2	26-Aug-05	EP1781802	21-Oct-09	27-Aug-25	Production Of Etanercept
35059	Luxembourg	8005732.6	28-Mar-08	EP1992697	17-Mar-10	27-Aug-25	Production Of Etanercept
35059	Macedonia	P-2009/411	26-Aug-05	903371	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Macedonia	P-2010/106	28-Mar-08	903574	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Malaysia	P120054023	26-Aug-05	MY-137803-A	31-Mar-09	26-Aug-25	Production Of Etanercept
35060	Malaysia	P120054022	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35059	Mexico	MX/A/2007/002381	26-Aug-05	268631	24-Jul-09	26-Aug-25	Production Of Etanercept
35060	Mexico	MX/A/2007/002382	26-Aug-05	265252	19-Mar-09	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
50640	Mexico	MX/A/2007/008777	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	Mexico	MX/A/2007/002380	26-Aug-05	270720	07-Oct-09	26-Aug-25	Production Of Polypeptides
35059	Morocco	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Monaco	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Montenegro						Production Of Etanercept
35059	Netherlands	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Netherlands	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	New Zealand	579208	20-Aug-09				Production Of Etanercept

35060	New Zealand	591233	18-Feb-11				Production Of Anti-Amyloid Beta Antibodies
52009	New Zealand	591232	18-Feb-11				Production Of Polypeptides
35059	New Zealand	554040	26/08/2005				Production Of Etanercept
35059	New Zealand	585733	27/05/2010				Production Of Etanercept
35059	Nicaragua	2007/0059	26-Aug-05				Production Of Etanercept
35060	Nicaragua	2007/0060	26-Aug-05	2086RPI	12-Dec-11	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
52009	Nicaragua	2007/0061	26-Aug-05				Production Of Polypeptides
35059	Norway	20071570	26-Aug-05				Production Of Etanercept
35060	Norway	20071571	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Norway	20071572	26-Aug-05				Production Of Polypeptides
35059	Pakistan	795/2005	26-Aug-05				Production Of Etanercept
35060	Pakistan	794/2005	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35059	Panama	86435-01	26-Aug-05	86435-01	18-Jul-08	26-Aug-25	Production Of Etanercept
35060	Panama	86436-01	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35059	Peru	000987-2005/OIN	26-Aug-05				Production Of Etanercept
35059	Peru	001227-2009/DIN	05-Nov-09				Production Of Etanercept
35060	Peru	000986-2005/OIN	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35060	Peru	001268-2009/DIN	23-Nov-09				Production Of Anti-Amyloid Beta Antibodies
35059	Philippines	1-2007-500475	26-Aug-05	1-2007-500475	20-Sep-10	26-Aug-25	Production Of Etanercept
35060	Philippines	1-2007-500476	26-Aug-05	1-2007-500476	19-Nov-10	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
52009	Philippines	1-2007-500474	26-Aug-05				Production Of Polypeptides
35059	Poland	5791482 2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Poland	8005732 6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Portugal	5791482 2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Portugal	8005732 6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Romania	5791482 2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Romania	8005732 6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Russian Federation	2007108717	26-Aug-05				Production Of Etanercept
35060	Russian Federation	2007108718	26-Aug-05	2418858	20-May-11	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
50640	Russian Federation	2007122451	24-Jan-06				Shear Protectants In Harvest Microfiltration
52009	Russian Federation	2007108719	26-Aug-05				Production Of Polypeptides
35059	Serbia	P-2009/875	26-Aug-05	51072	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Serbia	P-390/10	28-Mar-08	51255	04-Aug-10	26-Aug-25	Production Of Etanercept
35059	Singapore	200701310-5	26-Aug-05	129982	31-Dec-09	26-Aug-25	Production Of Etanercept
35060	Singapore	200905720-9	25-Aug-09				Production Of Anti-Amyloid Beta Antibodies
52009	Singapore	200907913-8	25-Nov-09				Production Of Polypeptides
35059	Slovak Republic	5791482 2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Slovak Republic	8005732 6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Slovenia	5791482 2	26-Aug-05	1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Slovenia	EP1992697	28-Mar-08	P200530984	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	South Africa	2007/01672	26-Aug-05				Production Of Etanercept
35060	South Africa	2007/02487	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	South Africa	2007/02483	26-Aug-05				Production Of Polypeptides
35059	Spain	5791482 2	26-Aug-05	2335518	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Spain	8005732 6	28-Mar-08	2341390	17-Mar-10	26-Aug-25	Production Of Etanercept

35059	Sweden	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Sweden	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Switzerland	5791482.2	26-Aug-05	EP1781802	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Switzerland	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Taiwan	94129077	25-Aug-05			24-Aug-25	Production Of Etanercept
35060	Taiwan	94129074	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Taiwan	94129070	25-Aug-05				Production Of Polypeptides
35059	Thailand	501004021	26-Aug-05				Production Of Etanercept
35060	Thailand	501004022	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
35059	Turkey	5791482.2	26-Aug-05	TR201000178T4	21-Oct-09	26-Aug-25	Production Of Etanercept
35059	Turkey	8005732.6	28-Mar-08	TR201003456T4	17-Mar-10	26-Aug-25	Production Of Etanercept
35059	Ukraine	A200703287	26-Aug-05	89383	25-Jan-10	26-Aug-25	Production Of Etanercept
35060	Ukraine	A200703284	26-Aug-05	89644	25-Feb-10	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
52009	Ukraine	A200703286	26-Aug-05	93859	25-Mar-11	26-Aug-25	Production Of Polypeptides
52009	United Arab Emirates	168/2007	26-Aug-05				Production Of Polypeptides
035059A	United States	11/213633	25-Aug-05	7300773	27-Nov-07	22-Dec-25	Production Of Etanercept
035060A	United States	11/213317	25-Aug-05	7335491	26-Feb-08	26-Sep-25	Production Of Anti-Amyloid Beta Antibodies
050640A	United States	11/2348214	24-Jan-06	7906024	15-Mar-11	06-Dec-29	Shear Protectants In Harvest Microfiltration
052009A	United States	11/213308	25-Aug-05	7294484	13-Nov-07	28-Oct-25	Production Of Polypeptides
35059	Venezuela	2005-001748	26-Aug-05				Production Of Etanercept
35060	Venezuela	2005-001747	26-Aug-05				Production Of Anti-Amyloid Beta Antibodies
52009	Venezuela	2005-001749	26-Aug-05				Production Of Polypeptides
35059	Vietnam	1-2007-00655	26-Aug-05	8813	18-Oct-10	26-Aug-25	Production Of Etanercept
35060	Vietnam	1-2007-00657	26-Aug-05	8625	26-Jul-10	26-Aug-25	Production Of Anti-Amyloid Beta Antibodies
52009	Vietnam	1-2007-00656	26-Aug-05	8624	26-Jul-10	26-Aug-25	Production Of Polypeptides

Esta es una copia verdadera certificada del documento original (sello ilegible)

Fechado el 18 día de abril de 2012

(firmado Patrick J.A. Kelly)

Patrick J. A. Kelly

5 Harbourmaster Place

IFSC Dublin 1

Notario público del Condado y la ciudad de Dublin

CESIÓN

Por un valor cierto, el recibo y adecuación del cual se reconoce aquí, **Wyeth Research Ireland Limited**, una compañía limitada privada creada en Irlanda (número de registro 403603) cuya oficina registrada está en Little Connell, Newbridge, County Kildare, Irlanda, por el presente vende, cede y transfiere a **Pfizer Ireland Pharmaceuticals**, una compañía ilimitada privada de Irlanda (número de registro 490938) cuya oficina registrada está en Operations Support Group, Ringaskiddy, County Cork, Irlanda, su entero derecho, título, e interés en y de cualquier solicitud de patente ó patente de la lista en el anexo adjunto al presente y que expresamente hace parte del presente; su entero derecho, título e interés, en todos los países del mundo, en y de todas las invenciones divulgadas en dichas solicitudes de patente y patentes; su entero derecho, título e interés, en todos los países del mundo, en y de todas las continuaciones, divisionales, continuación en parte, remisiones, reexámenes y extensiones de estos; su entero derecho, título e interés, en todos los países del mundo, en y de todas las solicitudes de patente y patentes en todos los países del mundo que reclaman la prioridad de las solicitudes de patente y patentes listadas en el anexo; su entero derecho, título e interés, si existe, en todos los países del mundo, en y de todas las solicitudes de patente y patentes en todos los países del mundo de las cuales las solicitudes de patente y patentes listadas en el anexo reclaman prioridad, y el derecho a reclamar prioridad de cualquiera de tales solicitudes de patente ó patentes bajo la Convención de Paris para la Protección de la Propiedad Industrial, y bajo cualquiera y todos los otros tratados y acuerdos de los cuales los Estado Unidos de America e Irlanda forman parte y que proporcionen privilegios de reivindicación de prioridad similares, en todos los países del mundo; lo mismo que el derecho para demandar a nombre de **Pfizer Ireland Pharmaceuticals** y recuperar los daños por infracciones pasadas de cualquiera de las solicitudes de patente ó patente cedidas en el presente;

Y **Wyeth Research Ireland Limited** acuerda aquí, siempre que se solicite, comunicar a dicho **Pfizer Ireland Pharmaceuticals** y sus sucesores y asignados, cualesquier hechos conocidos respecto de dichas invenciones, testificar en cualquier proceso legal con respecto a dichas invenciones, y firmar todos los documentos ó papeles necesarios para obtener y mantener la protección apropiada de las patentes de dichas invenciones en todos los países del mundo;

Y **Wyeth Research Ireland Limited** autoriza a **Pfizer Ireland Pharmaceuticals** ó su designado para suministrar cualquier solicitud de patente ó información de identificación de patentes faltantes ó corregir cualesquier errores en la solicitud de patente ó la información de identificación de patentes provistas aquí que se haya descubierto antes ó después del registro;

Y **Wyeth Research Ireland Limited** nombra aquí a **Pfizer Ireland Pharmaceuticals**, mediante su designado, su apoderado para firmar, en su nombre y por cuenta del mismo, cualquier y todos los documentos requeridos para efectuar esta Cesión, incluidos sin limitación cesiones, cesiones correctivas, poderes de abogado y otros papeles adicionales.

PRESENTE cuando el sello de

Wyeth Research Ireland Limited

Fue colocado en el presente y cuando este acto se dictó:

Por: (Firmado)

Por: (Firmado)

Nombre: Peter Duffy

Nombre: Paul Duffy

Cargo: Director

Cargo: Director

Nacionalidad: Irlandés

Nacionalidad: Irlandés

Dirección comercial:

Dirección comercial:

Little Connell

Little Connell

Newbridge

Newbridge

Co. Kildare

Co. Kildare

Testigo:

Testigo:

Por: (Firmado)

Por: (Firmado)

Nombre: Muireann Wangan	Nombre: Muireann Wangan
Cargo: Consejero Legal	Cargo: Consejero Legal
Nacionalidad: Irlandés	Nacionalidad: Irlandés
Dirección comercial:	Dirección comercial:
Ringaskiddy	Ringaskiddy
Cork	CO. Cork

Testigo:	Testigo:
Por: (Firmado)	Por: (Firmado)
Nombre: Toni Goggin	Nombre: Toni Goggin
Cargo: Asistente Gerencia	Cargo: Asistente Gerencia
Nacionalidad: Irlandés	Nacionalidad: Irlandés
Dirección comercial:	Dirección comercial:
Ringaskiddy	Ringaskiddy
Co. Cork	Co. Cork

Las anteriores firmas de Peter Duffy y Paul Duffy (Sello)

Son autenticadas por el presente

Fechado este 5 día de abril de 2012

(Firmado Patrick J. A. Kelly)	(Sello)	Patrick J. A. Kelly
		5 Harbourmaster Place,
		I.F.S.C
		Dublin 1
		Notario público del Condado y la
		De Dublin Comisionado de por
		Vida.

PRESENTE cuando el sello de

Pfizer Ireland Pharmaceuticals,

Fue colocado en el presente y cuando este acto se dictó:

Por: (Firmado)

Por: (Firmado)

Nombre: Peter Duffy

Nombre: Paul Duffy

Cargo: Director

Cargo: Director

Nacionalidad: Irlandés

Nacionalidad: Irlandés

Dirección comercial:

Dirección comercial:

Pfizer Ireland Pharmaceuticals,

Pfizer Ireland Pharmaceuticals,

Ringaskiddy

Ringaskiddy

Co. Cork

Co. Cork

Testigo:

Testigo:

Por: (Firmado)

Por: (Firmado)

Nombre: Muireann Wangan

Nombre: Muireann Wangan

Cargo: Consejero Legal

Cargo: Consejero Legal

Nacionalidad: Irlandés

Nacionalidad: Irlandés

Dirección comercial:

Dirección comercial:

Ringaskiddy

Ringaskiddy

Cork

CO. Cork

Testigo:

Testigo:

Por: (Firmado)

Por: (Firmado)

Nombre: Toni Goggin

Nombre: Toni Goggin

Cargo: Asistente Gerencia

Cargo: Asistente Gerencia

Nacionalidad: Irlandés

Nacionalidad: Irlandés

Dirección comercial:

Dirección comercial:

Ringaskiddy

Ringaskiddy

Co. Cork

Co. Cork

Las anteriores firmas de Peter Duffy y Paul Duffy (Sello)

Son autenticadas por el presente

Fechado este 5 día de abril de 2012

(Firmado Patrick J. A. Kelly) (Sello)

Patrick J. A. Kelly
5 Harbourmaster Place,
I.F.S.C
Dublin 1
Notario público del Condado y la
De Dublin Comisionado de por
Vida.

Protectores de corte en microfiltración de cultivos								
Núm. de Archivo	País	Número de Solicitud	Fecha de Solicitud	Número de Patente	Fecha Pat.	Fecha Expiración	Título	
35059	Albania	5791482.2	26-Ago-05	AL-P-2009-3226	21-Oct-09	26-Ago-25	Producción de Etanercept	
35059	Albania	AL-P-2010-3382	28-Mar-08	3323	13-Oct-10	26-Ago-25	Producción de Etanercept	
35059	Argentina	P050103595	26-Ago-05				Producción de Etanercept	
35060	Argentina	P050103595	26-Ago-05				Producción de anticuerpos antiamiloides beta	
52009	Argentina	P050103594	26-Ago-05				Producción de Polipeptidos	
35059	Australia	2005280036	26-Ago-05	2005280036	16-Feb-12	26-Ago-25	Producción de Etanercept	
35060	Australia	2005280090	26-Ago-05				Producción de anticuerpos antiamiloides beta	
35060	Australia	2012200353	20-Ene-12				Producción de anticuerpos antiamiloides beta	
50640	Australia	2006215313	24-Ene-06				Protectores de corte en microfiltración de cultivos	
52009	Australia	2005280034	26-Ago-05				Producción de Polipeptidos	
35059	Austria	5791482.2	26-Ago-05	E46376	21-Oct-09	26-Ago-25	Producción de Etanercept	
35059	Austria	8005732.6	28-Mar-08	E461265	17-Mar-10	26-Ago-25	Producción de Etanercept	
35059	Belgica	5791482.2	26-Ago-05	EP1781802	21-Oct-09	26-Ago-25	Producción de Etanercept	
35059	Belgica	8005732.6	28-Mar-08	EP1992697	17-Mar-10	26-Ago-25	Producción de Etanercept	
35059	Bosnia-Herzegovina	5791482.2	26-Ago-05	1781802	21-Oct-09	26-Ago-25	Producción de Etanercept	
35059	Bosnia-Herzegovina	8005732.6	28-Mar-08	1992967	17-Mar-10	26-Ago-25	Producción de Etanercept	
35058	Brazil	PI 0514694-1	26-Ago-05				Producción de Etanercept	
35060	Brazil	PI0514680-1	26-Ago-05				Producción de anticuerpos antiamiloides beta	
50640	Brazil	PI0607269-0	24-Ene-06				Protectores de corte en microfiltración de cultivos	
52009	Brazil	PI0514703-4	26-Ago-05				Producción de Polipeptidos	
35059	Bulgaria	5791482.2	26-Ago-05	EP1781802	21-Oct-09	26-Ago-25	Producción de Etanercept	
35059	Bulgaria	8005732.6	28-Mar-08	BG/EP1992697T3	17-Mar-10	26-Ago-25	Producción de Etanercept	
35059	Canada	2578138	26-Ago-05	2578138	05-Oct-10	26-Ago-25	Producción de Etanercept	
35060	Canada	2578137	26-Ago-05	2578137	09-Nov-10	26-Ago-25	Producción de anticuerpos antiamiloides beta	
50640	Canada	2594580	24-Ene-06				Protectores de corte en microfiltración de cultivos	
52009	Canada	2578141	26-Ago-05				Producción de Polipeptidos	
35059	Chile	2183/2005	26-Ago-05				Producción de Etanercept	
35060	Chile	2185/2005	26-Ago-05				Producción de anticuerpos antiamiloides beta	
52009	Chile	2184/2005	26-Ago-05				Producción de Polipeptidos	
35059	China P.R.	200580036938.8	26-Ago-05				Producción de Etanercept	
35060	China P.R.	200580036897.2	26-Ago-05				Producción de anticuerpos antiamiloides beta	
50640	China P.R.	200680003134.2	24-Ene-06				Protectores de corte en microfiltración de cultivos	
52009	China P.R.	200580036899.1	26-Ago-05				Producción de Polipeptidos	
35059	Colombia	07 030 535	26-Ago-05				Producción de Etanercept	
35060	Colombia	7030534	26-Ago-05				Producción de anticuerpos antiamiloides beta	
52009	Colombia	07 030 529	26-Ago-05				Producción de Polipeptidos	
35059	Costa Rica	8998	26-Ago-05				Producción de Etanercept	
35060	Costa Rica	8996	26-Ago-05				Producción de anticuerpos antiamiloides beta	
52009	Costa Rica	8997	26-Ago-05				Producción de Polipeptidos	
35059	Croatia	5791482.2	26-Ago-05	P20100614	21-Oct-09	26-Ago-25	Producción de Etanercept	
35059	Croatia	8005732.6	28-Mar-08	P20100271	17-Mar-10	26-Ago-25	Producción de Etanercept	
35059	Cyprus	5791482.2	26-Ago-05	CY1109721	21-Oct-09	26-Ago-25	Producción de Etanercept	
35059	Cyprus	8005732.6	28-Mar-08	CY1110092	17-Mar-10	26-Ago-25	Producción de Etanercept	
35059	Repubblica Checa	5791482.2	26-Ago-05	EP1781802	21-Oct-09	26-Ago-25	Producción de Etanercept	